Pharma firm’s acquisitions performing well in Q1

CHESHIRE-based pharmaceuticals business Dechra says its first-quarter performance was in line with expectations with its acquisitions including Apex, based in Sydney, Australia, for £31.m performing well.

Dechra, headquartered in Northwich with its main manufacturing base in Skipton, North Yorkshire, said its generic antibiotic, Amoxiclav, had received approval from the US Food and Drug Administration (FDA).
 
The registration is for two of four different dosage strengths of tablets; the remaining two are currently in the final stage of registration with approval expected prior to the end of the 2016 calendar year.

Amoxiclav is the most significant product within the recently acquired Putney pipeline and its formal approval is a major achievement by the group’s development and regulatory team.

Meanwhile, following the listed company’s annual meeting today (Friday October 21), its chairman Michael Redmond will retire.

Tony Rice will take up the role as non-executive chairman after the AGM.

A statement released by Dechra said: “We would like to thank for the huge contribution and guidance he has provided to the business throughout his tenure. We wish him and his family well in his retirement.”

Close